ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Sumitomo Dainippon Pharma Co., Ltd.

  • 2,761.00 JPY
  • +1.00
  • +0.04%
  • Japan
    Feb 22, 2019
  • Ticker
    TKS(4506)
  • Prev. close
    2,760
  • Market cap (JPY)
    1,098.20B
  • Market cap (USD)
    9,908.01M
  • Shares
    397.90M

Business Summary

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacturing, sale, import and export of pharmaceuticals products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment handles the creation of new pharmaceutical products. The Other Business segment division includes food ingredients and additives, chemical products materials, veterinary drugs, and diagnostics. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue466,838M4,212.10M
Gross Profit347,955M3,139.46M
Operating income79,643M718.58M
Income before tax84,866M765.71M
Net income53,448M482.24M
EBITDA92,530M834.86M
Diluted EPS134.531.21
Dividends Per Share280.25
Total Assets809,684M7,613.38M
Total liabilities356,961M3,356.47M
Total equity452,723M4,256.91M
Operating cash flow93,420M842.89M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 387,693M 371,370M 403,206M 408,357M 466,838M
Gross Profit 269,223M 265,014M 293,016M 307,911M 347,955M
Operating income 42,142M 23,275M 36,929M 60,974M 79,643M
Income before tax 34,709M 33,755M 39,560M 42,781M 84,866M
Net income 20,060M 15,447M 24,697M 31,316M 53,448M
EBITDA 68,918M 42,501M 57,194M 73,687M 92,530M
Diluted EPS 50.49 38.88 62.16 78.82 134.53
Dividends Per Share 18 18 18 20 28
Total Assets 659,032M 711,583M 707,715M 779,072M 809,684M
Total liabilities 260,492M 260,562M 261,243M 366,804M 356,961M
Total equity 398,540M 451,021M 446,472M 412,268M 452,723M
Operating cash flow 49,943M 32,523M 52,486M 19,143M 93,420M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 3,870.29M 3,380.50M 3,357.69M 3,771.04M 4,212.10M
Gross Profit 2,687.62M 2,412.36M 2,440.08M 2,843.45M 3,139.46M
Operating income 420.69M 211.86M 307.52M 563.07M 718.58M
Income before tax 346.49M 307.26M 329.43M 395.06M 765.71M
Net income 200.25M 140.61M 205.66M 289.19M 482.24M
EBITDA 688.00M 386.87M 476.28M 680.47M 834.86M
Diluted EPS 0.50 0.35 0.51 0.72 1.21
Dividends Per Share 0.17 0.16 0.14 0.18 0.25
Total Assets 6,399.30M 5,933.56M 6,296.67M 6,991.58M 7,613.38M
Total liabilities 2,529.41M 2,172.70M 2,324.32M 3,291.78M 3,356.47M
Total equity 3,869.88M 3,760.85M 3,972.34M 3,699.79M 4,256.91M
Operating cash flow 498.57M 296.04M 437.07M 176.77M 842.89M

Valuation Measures

Mar 2018
PER13.27
ROA6.72%
ROE12.35%
Operating margin17.06%
Profit margin11.44%

Key executives

  • President & Representative Director: Hiroshi Nomura
  • Director, Executive Officer & GM-Development: Nobuyuki Hara
  • General Manager-Research Technology: Yoshiharu Ikeda
  • Director & Executive Officer: Toru Kimura
  • Executive Officer: Antony Loebel

Shareholders

  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Inabata & Co., Ltd. (5.1%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • Nippon Life Insurance Co. (1.9%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Nikko Asset Management Co., Ltd. (1.6%)
  • Daiwa Asset Management Co. Ltd. (1.5%)
  • Sumitomo Life Insurance Co. (1.4%)
  • MS&AD Insurance Group Holdings, Inc. (1.4%)
  • The Vanguard Group, Inc. (1.0%)

Contact Details

Related Companies

  • Dainippon Sumitomo Pharma America Holdings, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co. Ltd.
  • Sunovion Pharmaceuticals Europe Ltd.
  • Sumitomo Dainippon Pharma Trust
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.

Competitors

  • Intra-Cellular Therapies, Inc.
  • VistaGen Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.
  • ACADIA Pharmaceuticals Inc.
  • Xenon Pharmaceuticals Inc.
  • Voyager Therapeutics, Inc.
  • ArQule, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • SCYNEXIS, Inc.
  • Innoviva, Inc.
  • Neos Therapeutics, Inc.
  • Axovant Sciences Ltd
  • Marinus Pharmaceuticals Inc
  • Verona Pharma plc
  • Circassia Pharmaceuticals Plc
  • Supernus Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • Stemline Therapeutics, Inc.
  • Arcturus Therapeutics Ltd
  • OptiNose, Inc.
Last Updated on 22 Feb, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media